NCT00581620View on ClinicalTrials.gov

Study Evaluating Prevenar Immunogenicity in High Risk Children

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

September 30, 2007

Conditions
Vaccines, Pneumococcal Conjugate Vaccine
Interventions
BIOLOGICAL

pneumococcus conjugate vaccine

Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00581620 - Study Evaluating Prevenar Immunogenicity in High Risk Children | Biotech Hunter | Biotech Hunter